Company News

Share this article:
Gilead Sciences closing two cardiovascular-focused research and development offices in Colorado. The closures stem from Gilead's acquisition of California-based CV Therapeutics, according to an Associated Press report. A spokesperson for Gilead said the company is consolidating its operations in California.

AstraZeneca partnered with Forest Laboratories for the development and commercialization of ceftaroline, an experimental antibiotic. The partnership includes markets outside of the US, Canada and Japan. Financial terms of the deal were not disclosed.   

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.